PHAXIAM Therapeutics Investor Relations Material
Latest events
Q2 2024
PHAXIAM Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from PHAXIAM Therapeutics SA
Access all reports
PHAXIAM Therapeutics S.A. is a biopharmaceutical company focused on developing innovative treatments for drug-resistant bacterial infections. Leveraging phages, which are viruses that specifically target and kill bacteria, the company is developing a portfolio aimed at combating some of the most challenging and resistant bacterial strains, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. PHAXIAM is also involved in advancing clinical-stage therapies, including eryaspase, which is being tested in late-stage clinical trials for conditions such as pancreatic cancer and acute lymphoblastic leukemia. The company is headquartered in Lyon, France, and its shares are listed on the Euronext Paris.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
PHXM
Country
🇫🇷 France